Holen Sie sich die Stockscreener-App
0.8877
1.37%
-0.0123
Handel nachbörslich:
.87
-0.0177
-1.99%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CTXR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.90
Offen:
$0.89
24-Stunden-Volumen:
273.91K
Relative Volume:
0.25
Marktkapitalisierung:
$18.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-39.14M
KGV:
-0.1487
EPS:
-5.97
Netto-Cashflow:
$-28.20M
1W Leistung:
+4.68%
1M Leistung:
-26.02%
6M Leistung:
-49.85%
1J Leistung:
-76.07%
1-Tages-Spanne:
$0.8311
$0.90
1-Wochen-Bereich:
$0.8311
$0.99
52-Wochen-Spanne:
$0.63
$3.815
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Firmenname
Citius Pharmaceuticals Inc
Sektor
Branche
Telefon
(908) 967-6676
Adresse
11 COMMERCE DRIVE, CRANFORD, NJ
Vergleichen Sie CTXR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
0.8877 | 18.69M | 0 | -39.14M | -28.20M | -5.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2021-11-30 | Eingeleitet | Maxim Group | Buy |
Citius Pharmaceuticals Inc Aktie (CTXR) Neueste Nachrichten
Will Citius Pharmaceuticals Inc. (47N0) stock outperform Dow Jones2025 Geopolitical Influence & Entry and Exit Point Strategies - ulpravda.ru
Will Citius Pharmaceuticals Inc. stock continue upward momentumJuly 2025 Drop Watch & Technical Entry and Exit Alerts - ulpravda.ru
How Citius Pharmaceuticals Inc. (47N0) stock expands through international marketsMarket Growth Report & Consistent Profit Trade Alerts - ulpravda.ru
Can Citius Pharmaceuticals Inc. (47N0) stock resist broad market declinesJuly 2025 Big Picture & High Conviction Investment Ideas - ulpravda.ru
Can Citius Pharmaceuticals Inc. stock attract ESG capital inflowsRecession Risk & Real-Time Volume Triggers - ulpravda.ru
Portfolio Update: Can Citius Pharmaceuticals Inc 47N0 stock resist broad market declinesJuly 2025 Chart Watch & Safe Capital Allocation Plans - moha.gov.vn
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - GuruFocus
Citius Oncology announces pricing of $9 million public offering - MSN
Fibonacci Retracement Aligns with Support in Thomas Scott India LimitedAnalyst Upgrades & Small Capital Trading Tips - earlytimes.in
Is Citius Pharmaceuticals Inc 47N0 a good long term investmentMarket Sentiment Report & Free Long-Term Investment Planning - earlytimes.in
Citius Pharmaceuticals Inc (CTXRW) Fundamental Analysis - Meyka
Market Outlook: What dividend safety score for Citius Pharmaceuticals Inc stockAnalyst Downgrade & Risk Managed Investment Strategies - moha.gov.vn
CITIUS PHARMACEUTICALS Q4 2025 Earnings Preview: Recent $CTXR Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Dow Gains Over 100 Points; US Jobless Claims Decline - Benzinga
Stock Market Today: Dow Jones, Nasdaq Futures Slip On Christmas Eve Despite Strong Q3 GDP Report— UiPath, AST SpaceMobile, Ramaco In Focus (UPDATED) - Benzinga
Stock Market Today: Dow Jones, S&P 500 Futures Drop On Christmas Eve Despite Strong Q3 GDP Report—UiPath, AST SpaceMobile, Ramaco Resources In Focus - Sahm
Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why - Benzinga
UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday - Benzinga
Citius Pharmaceuticals Inc. Full Year Loss Decreases - Nasdaq
Citius Pharmaceuticals (CTXR) Reports Wider Annual Loss - GuruFocus
Citius Pharma launches cancer immunotherapy LYMPHIR in the U.S. By Investing.com - Investing.com Nigeria
Citius Pharmaceuticals, Inc. reports fiscal year 2025 financial results and provides business update - marketscreener.com
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update - TradingView — Track All Markets
Citius Oncology Transitions to Commercial Stage: Analyzing the 10-K Filing and the 2026 Outlook for LYMPHIR - FinancialContent
Citius Pharmaceuticals (CTXR) Reports Earnings Miss with Increas - GuruFocus
Citius Pharma launches cancer immunotherapy LYMPHIR in the U.S. - Investing.com
CTXR: LYMPHIR's U.S. launch marks a pivotal year, with strong capital raises and ongoing pipeline progress - TradingView — Track All Markets
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - WV News
Citius Pharmaceuticals, Inc. SEC 10-K Report - TradingView — Track All Markets
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 - marketscreener.com
How interest rate cuts could boost Citius Pharmaceuticals Inc. stockShort Setup & Stock Portfolio Risk Management - Улправда
Why Citius Pharmaceuticals Inc. stock remains resilientPortfolio Performance Report & Technical Pattern Based Buy Signals - Улправда
Is Citius Pharmaceuticals Inc. (47N0) stock a safe buy pre earningsExit Point & Daily Oversold Bounce Ideas - Bölüm Sonu Canavarı
Can Citius Pharmaceuticals Inc. stock resist market sell offsWeekly Stock Summary & Proven Capital Preservation Tips - Улправда
Sell Signal: How Citius Pharmaceuticals Inc. stock trades before earnings2025 Biggest Moves & Daily Growth Stock Investment Tips - Улправда
What analyst consensus says on Citius Pharmaceuticals Inc. stockJuly 2025 Recap & Low Risk High Win Rate Picks - DonanımHaber
Analyst Calls: Will Citius Pharmaceuticals Inc. stock maintain dividend yieldInsider Selling & Precise Trade Entry Recommendations - DonanımHaber
Will Citius Pharmaceuticals Inc. (47N0) stock outperform energy sector in 2025July 2025 Big Picture & Free Weekly Chart Analysis and Trade Guides - DonanımHaber
Will Citius Pharmaceuticals Inc. stock maintain dividend yieldTrade Ideas & Free Real-Time Volume Trigger Notifications - DonanımHaber
Will Citius Pharmaceuticals Inc. stock see insider buyingJuly 2025 Chart Watch & Real-Time Buy Signal Alerts - DonanımHaber
Citius Pharmaceuticals Earnings Notes - Trefis
Is Citius Pharmaceuticals Inc. stock positioned for digital transformationOil Prices & Real-Time Volume Surge Alerts - ulpravda.ru
Why Citius Pharmaceuticals Inc. stock remains a top recommendationJuly 2025 Reactions & Real-Time Chart Breakout Alerts - Улправда
Quarterly Earnings: How interest rate cuts could boost Citius Pharmaceuticals Inc. stockAnalyst Upgrade & Accurate Entry/Exit Alerts - Улправда
Citius Oncology closes $18 million in offerings to support LYMPHIR launch - Investing.com Nigeria
Citius Oncology Announces Closing of $18 Million Concurrent Regi - GuruFocus
Citius Oncology closes $18 million in offerings to support LYMPHIR launch By Investing.com - Investing.com South Africa
Citius Oncology (Nasdaq: CTOR) raises $18M at-the-market to fund LYMPHIR - Stock Titan
Citius Oncology shares sink after announcing $18M fundraising deal - MSN
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Finviz
Aug Selloffs: Is Citius Pharmaceuticals Inc stock positioned for digital transformationPortfolio Gains Summary & Free Real-Time Volume Trigger Notifications - moha.gov.vn
Finanzdaten der Citius Pharmaceuticals Inc-Aktie (CTXR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):